Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Alexey Aleshin"'
Autor:
Huffman BM; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Jurdi A; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Aleshin A; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Liu MC; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Klempner SJ; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2023 Mar; Vol. 7, pp. e2300043.
Autor:
Kasi PM; Pashtoon M. Kasi, MD, MS, Weill Cornell Medicine, Meyer Cancer Center, Englander Institute of Precision Medicine, New York-Presbyterian Hospital, New York, NY; Gordon Fehringer, PhD and Alexey Aleshin, MD, Natera Inc, Austin, TX; and Scott Kopetz, MD, PhD, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Fehringer G; Pashtoon M. Kasi, MD, MS, Weill Cornell Medicine, Meyer Cancer Center, Englander Institute of Precision Medicine, New York-Presbyterian Hospital, New York, NY; Gordon Fehringer, PhD and Alexey Aleshin, MD, Natera Inc, Austin, TX; and Scott Kopetz, MD, PhD, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Aleshin A; Pashtoon M. Kasi, MD, MS, Weill Cornell Medicine, Meyer Cancer Center, Englander Institute of Precision Medicine, New York-Presbyterian Hospital, New York, NY; Gordon Fehringer, PhD and Alexey Aleshin, MD, Natera Inc, Austin, TX; and Scott Kopetz, MD, PhD, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Kopetz S; Pashtoon M. Kasi, MD, MS, Weill Cornell Medicine, Meyer Cancer Center, Englander Institute of Precision Medicine, New York-Presbyterian Hospital, New York, NY; Gordon Fehringer, PhD and Alexey Aleshin, MD, Natera Inc, Austin, TX; and Scott Kopetz, MD, PhD, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2022 Jul; Vol. 6, pp. e2200275.